Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A et al (2021) Global cancer statistics 2020: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209–249

Article  PubMed  Google Scholar 

Li GZ, Doherty GM, Wang J (2022) Surgical management of gastric cancer: a review. JAMA Surg 157:446–454

Article  PubMed  Google Scholar 

Nishizaki D, Ganeko R, Hoshino N, Hida K, Obama K, Furukawa TA et al (2021) Roux-en-Y versus Billroth-I reconstruction after distal gastrectomy for gastric cancer. Cochrane Database Syst Rev 9:012998

Google Scholar 

Cai Z, Liu C, Ji G, Chen J, Mu M, Jiang Z et al (2022) Uncut Roux-en-Y reconstruction after distal gastrectomy for gastric cancer. Cochrane Database Syst Rev 6:015014

Google Scholar 

Smyth EC, Nilsson M, Grabsch HI, van Grieken NC, Lordick F (2020) Gastric cancer. Lancet 396:635–648

Article  CAS  PubMed  Google Scholar 

Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJH, Nicolson M et al (2006) Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355:11–20

Article  CAS  PubMed  Google Scholar 

Ferri LE, Ades S, Alcindor T, Chasen M, Marcus V, Hickeson M et al (2012) Perioperative docetaxel, cisplatin, and 5-fluorouracil (DCF) for locally advanced esophageal and gastric adenocarcinoma: a multicenter phase II trial. Ann Oncol 23:1512–1517

Article  CAS  PubMed  Google Scholar 

Ychou M, Boige V, Pignon J-P, Conroy T, Bouché O, Lebreton G et al (2011) Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol 29:1715–1721

Article  CAS  PubMed  Google Scholar 

Cai Z, Yin Y, Yin Y, Shen C, Wang J, Yin X et al (2018) Comparative effectiveness of adjuvant treatments for resected gastric cancer: a network meta-analysis. Gastric Cancer 21:1031–1040

Article  PubMed  Google Scholar 

Cai Z, Yin Y, Zhao Z, Xin C, Cai Z, Yin Y et al (2018) Comparative effectiveness of neoadjuvant treatments for resectable gastroesophageal cancer: a network meta-analysis. Front Pharmacol 9:872

Article  PubMed  PubMed Central  Google Scholar 

Cai Z, Yin Y, Shen C, Wang J, Yin X, Chen Z et al (2018) Comparative effectiveness of preoperative, postoperative and perioperative treatments for resectable gastric cancer: a network meta-analysis of the literature from the past 20 years. Surg Oncol 27:563–574

Article  PubMed  Google Scholar 

Zhang X, Liang H, Li Z, Xue Y, Wang Y, Zhou Z et al (2021) Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial. Lancet Oncol 22:1081–1092

Article  CAS  PubMed  Google Scholar 

Jung YD, Mansfield PF, Akagi M, Takeda A, Liu W, Bucana CD et al (2002) Effects of combination anti-vascular endothelial growth factor receptor and anti-epidermal growth factor receptor therapies on the growth of gastric cancer in a nude mouse model. Eur J Cancer 38:1133–1140

Article  CAS  PubMed  Google Scholar 

Li J, Qin S, Xu J, Xiong J, Wu C, Bai Y et al (2016) Randomized, double-blind, placebo-controlled phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction. J Clin Oncol 34:1448–1454

Article  CAS  PubMed  Google Scholar 

Zheng Y, Yang X, Yan C, Feng R, Sah BK, Yang Z et al (2020) Effect of apatinib plus neoadjuvant chemotherapy followed by resection on pathologic response in patients with locally advanced gastric adenocarcinoma: a single-arm, open-label, phase II trial. Eur J Cancer 130:12–19

Article  CAS  PubMed  Google Scholar 

Markham A, Keam SJ (2019) Camrelizumab: first global approval. Drugs 79:1355–1361

Article  PubMed  Google Scholar 

Mo H, Huang J, Xu J, Chen X, Wu D, Qu D et al (2018) Safety, anti-tumour activity, and pharmacokinetics of fixed-dose SHR-1210, an anti-PD-1 antibody in advanced solid tumours: a dose-escalation, phase 1 study. Br J Cancer 119:538–545

Article  CAS  PubMed  PubMed Central  Google Scholar 

Huang J, Mo H, Zhang W, Chen X, Qu D, Wang X et al (2019) Promising efficacy of SHR-1210, a novel anti-programmed cell death 1 antibody, in patients with advanced gastric and gastroesophageal junction cancer in China. Cancer 125:742–749

Article  CAS  PubMed  Google Scholar 

Peng Z, Wei J, Wang F, Ying J, Deng Y, Gu K et al (2021) Camrelizumab combined with chemotherapy followed by camrelizumab plus apatinib as first-line therapy for advanced gastric or gastroesophageal junction adenocarcinoma. Clin Cancer Res 27:3069–3078

Article  CAS  PubMed  Google Scholar 

Chan A-W, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K et al (2013) SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med 158:200–207

Article  PubMed  PubMed Central  Google Scholar 

Nakamura K, Kuwata T, Shimoda T, Mizusawa J, Katayama H, Kushima R et al (2015) Determination of the optimal cutoff percentage of residual tumors to define the pathological response rate for gastric cancer treated with preoperative therapy (JCOG1004-A). Gastric Cancer 18:597–604

Article  CAS  PubMed  Google Scholar 

Becker K, Mueller JD, Schulmacher C, Ott K, Fink U, Busch R et al (2003) Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer 98:1521–1530

Article  PubMed  Google Scholar 

Dindo D, Demartines N, Clavien P-A (2004) Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240:205–213

Article  PubMed  PubMed Central  Google Scholar 

Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1–10

Article  CAS  PubMed  Google Scholar 

Ajani JA, D’Amico TA, Bentrem DJ, Chao J, Cooke D, Corvera C et al (2022) Gastric cancer, version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 20:167–192

Article  CAS  PubMed  Google Scholar 

Wang F-H, Zhang X-T, Li Y-F, Tang L, Qu X-J, Ying J-E et al (2021) The Chinese society of clinical oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer, 2021. Cancer Commun (Lond) 41:747–795

Article  PubMed  Google Scholar 

Japanese Gastric Cancer Association (2021) Japanese gastric cancer treatment guidelines 2018. Gastric Cancer 24:1–21

Article  Google Scholar 

Lin J-X, Xu Y-C, Lin W, Xue F-Q, Ye J-X, Zang W-D et al (2021) Effectiveness and safety of apatinib plus chemotherapy as neoadjuvant treatment for locally advanced gastric cancer: a nonrandomized controlled trial. JAMA Netw Open 4:e2116240

Article  PubMed  PubMed Central  Google Scholar 

Li J-Y, Chen Y-P, Li Y-Q, Liu N, Ma J (2021) Chemotherapeutic and targeted agents can modulate the tumor microenvironment and increase the efficacy of immune checkpoint blockades. Mol Cancer 20:27

Article  PubMed  PubMed Central  Google Scholar 

Heinhuis KM, Ros W, Kok M, Steeghs N, Beijnen JH, Schellens JHM (2019) Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors. Ann Oncol 30:219–235

Article  CAS  PubMed  Google Scholar 

Zhang Y, Wang F, Sun H-R, Huang Y-K, Gao J-P, Huang H (2021) Apatinib combined with PD-L1 blockade synergistically enhances antitumor immune responses and promotes HEV formation in gastric cancer. J Cancer Res Clin Oncol 147:2209–2222

Article  CAS  PubMed  Google Scholar 

Yi M, Jiao D, Qin S, Chu Q, Wu K, Li A (2019) Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment. Mol Cancer 18:60

Article  PubMed